向P21激活激酶抑制了T细胞淋巴细胞淋巴瘤的增殖,并增强了T细胞淋巴细胞淋巴瘤的化学敏感性
Ning Su1,2,3,4, Yu Fang1,2,4,5, Xu Chen4,6
1Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Blood science (Baltimore, Md.)
|November 9, 2023
概括
P21激活激酶 (PAK) 在T细胞淋巴细胞淋巴瘤 (T-LBL) 中升高,并与预后不佳有关. 用药物抑制PAK抑制了T-LBL细胞生长并提高了化疗的有效性,这表明PAK是治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症遗传学 癌症遗传学
背景情况:
- T细胞淋巴细胞淋巴瘤 (T-LBL) 是一种具有不良患者结局的侵袭性非霍奇金淋巴瘤.
- P21激活激酶 (PAK) 涉及T-LBL预后,但其在疾病进展和生存中的作用尚不清楚.
- 了解PAK的功能对于开发新型T-LBL疗法至关重要.
研究的目的:
- 调查PAK在T-LBL进展和生存中的作用.
- 评估PAK抑制剂在T-LBL中的治疗潜力.
- 阐明T-LBL中PAK抑制的基础分子机制.
主要方法:
- 在T-LBL细胞系和患者样本中对PAK1和PAK2表达的比较分析.
- 对PAK抑制剂对T-LBL细胞增殖和细胞周期进展的影响的评估.
- 在体外和体内评估PAK抑制剂介导的对多克索鲁比辛的化学敏感化.
- 西方涂抹和RNA测序以确定PAK抑制的分子标.
主要成果:
- 与正常的T-淋巴细胞相比,T-LBL细胞系中的PAK1表达显著更高.
- 在复发的T-LBL患者中观察到高的PAK2mRNA水平.
- 在T-LBL患者中,高PAK1和PAK2表达与较短的无复发存活 (RFS) 相相关.
- PAK抑制剂 (PF3758309和FRAX597) 通过阻断G1/S阶段过渡来抑制T-LBL细胞的增殖.
- 在体外和体内,PF3758309增强了多克索鲁比辛的化学敏感性.
- PF3758309抑制了PAK1/2酸化,并降低了循环D1,NF-κB和细胞粘附通路的调节.
结论:
- PAK表达与T-LBL复发和预后不佳有关.
- PAK抑制剂通过抑制T-LBL细胞增殖,显示出其作为治疗剂的潜力.
- 抑制PAK可以增强T-LBL细胞对多克索鲁比的化学敏感性.
- 向PAK是T-LBL治疗的一个有前途的治疗策略.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K


